GlaxoSmithKline plc (LON:GSK) insider Patrick Vallance sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of GBX 1,310 ($17.63), for a total value of £262,000 ($352,624.50).

Patrick Vallance also recently made the following trade(s):

  • On Thursday, November 9th, Patrick Vallance purchased 10 shares of GlaxoSmithKline stock. The stock was bought at an average price of GBX 1,364 ($18.36) per share, with a total value of £136.40 ($183.58).

GlaxoSmithKline plc (LON:GSK) opened at GBX 1,310 ($17.63) on Thursday. GlaxoSmithKline plc has a 52-week low of GBX 1,270 ($17.09) and a 52-week high of GBX 1,724.50 ($23.21).

GlaxoSmithKline (LON:GSK) last announced its earnings results on Wednesday, October 25th. The company reported GBX 32.50 ($0.44) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of GBX 31.80 ($0.43) by GBX 0.70 ($0.01). The company had revenue of GBX 784.30 billion for the quarter. GlaxoSmithKline had a return on equity of 461.88% and a net margin of 17.79%.

The company also recently declared a dividend, which will be paid on Thursday, January 11th. Investors of record on Thursday, November 9th will be given a dividend of GBX 19 ($0.26) per share. This represents a dividend yield of 1.41%. The ex-dividend date of this dividend is Thursday, November 9th.

A number of research firms have weighed in on GSK. UBS set a GBX 1,550 ($20.86) price target on GlaxoSmithKline and gave the stock a “buy” rating in a report on Wednesday, December 13th. Investec cut GlaxoSmithKline to a “hold” rating and decreased their price target for the stock from GBX 1,800 ($24.23) to GBX 1,390 ($18.71) in a report on Monday, November 6th. Citigroup restated a “neutral” rating and issued a GBX 1,400 ($18.84) price target on shares of GlaxoSmithKline in a report on Wednesday, December 13th. Berenberg Bank restated a “buy” rating and issued a GBX 1,760 ($23.69) price target on shares of GlaxoSmithKline in a report on Wednesday, December 13th. Finally, J P Morgan Chase & Co restated a “neutral” rating on shares of GlaxoSmithKline in a report on Thursday, September 21st. Three research analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have assigned a buy rating to the company’s stock. GlaxoSmithKline currently has a consensus rating of “Hold” and an average price target of GBX 1,562.86 ($21.03).

TRADEMARK VIOLATION NOTICE: “GlaxoSmithKline plc (GSK) Insider Sells £262,000 in Stock” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright law. The legal version of this article can be read at

GlaxoSmithKline Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Insider Buying and Selling by Quarter for GlaxoSmithKline (LON:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with's FREE daily email newsletter.